Cargando…

Transferrin as a thermosensitizer in radiofrequency hyperthermia for cancer treatment

One of the main characteristics of cancer tissues is poor development of neovascularization that results in a limited blood circulation. Because of this phenomenon, it is harder for cancer tissues to diffuse their elevated heat into other parts of the body. The scientific principle of radiofrequency...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Hea-Jong, Lee, Heui-Kwan, Kwon, Ki Beom, Kim, Hyeon-Jin, Hong, Seong-Tshool
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131143/
https://www.ncbi.nlm.nih.gov/pubmed/30202000
http://dx.doi.org/10.1038/s41598-018-31232-9
_version_ 1783354044601860096
author Chung, Hea-Jong
Lee, Heui-Kwan
Kwon, Ki Beom
Kim, Hyeon-Jin
Hong, Seong-Tshool
author_facet Chung, Hea-Jong
Lee, Heui-Kwan
Kwon, Ki Beom
Kim, Hyeon-Jin
Hong, Seong-Tshool
author_sort Chung, Hea-Jong
collection PubMed
description One of the main characteristics of cancer tissues is poor development of neovascularization that results in a limited blood circulation. Because of this phenomenon, it is harder for cancer tissues to diffuse their elevated heat into other parts of the body. The scientific principle of radiofrequency hyperthermia relies on this quality of cancer tissues which with higher temperature becomes more apparent. Despite the obvious necessity to selectively heat the cancer tissue for radiofrequency hyperthermia, a proper thermosensitizer has not been developed until now. Here, we show that transferrin containing ferric ion could be an ideal thermosensitizer for the increased efficiency of radiofrequency hyperthermia. In our result, the ferric ion-enriched cancer tissues dramatically react with 13.56 MHz radiofrequency wave to cause cancer-selective dielectric temperature increment. The overall anticancer efficacy of a 13.56 MHz radiofrequency hyperthermia using transferrin as a thermosensitizer was much higher than the oncotherapeutic efficacy of paclitaxel, successfully eradicating cancer in a tumor-xenografted mouse experiment.
format Online
Article
Text
id pubmed-6131143
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-61311432018-09-13 Transferrin as a thermosensitizer in radiofrequency hyperthermia for cancer treatment Chung, Hea-Jong Lee, Heui-Kwan Kwon, Ki Beom Kim, Hyeon-Jin Hong, Seong-Tshool Sci Rep Article One of the main characteristics of cancer tissues is poor development of neovascularization that results in a limited blood circulation. Because of this phenomenon, it is harder for cancer tissues to diffuse their elevated heat into other parts of the body. The scientific principle of radiofrequency hyperthermia relies on this quality of cancer tissues which with higher temperature becomes more apparent. Despite the obvious necessity to selectively heat the cancer tissue for radiofrequency hyperthermia, a proper thermosensitizer has not been developed until now. Here, we show that transferrin containing ferric ion could be an ideal thermosensitizer for the increased efficiency of radiofrequency hyperthermia. In our result, the ferric ion-enriched cancer tissues dramatically react with 13.56 MHz radiofrequency wave to cause cancer-selective dielectric temperature increment. The overall anticancer efficacy of a 13.56 MHz radiofrequency hyperthermia using transferrin as a thermosensitizer was much higher than the oncotherapeutic efficacy of paclitaxel, successfully eradicating cancer in a tumor-xenografted mouse experiment. Nature Publishing Group UK 2018-09-10 /pmc/articles/PMC6131143/ /pubmed/30202000 http://dx.doi.org/10.1038/s41598-018-31232-9 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Chung, Hea-Jong
Lee, Heui-Kwan
Kwon, Ki Beom
Kim, Hyeon-Jin
Hong, Seong-Tshool
Transferrin as a thermosensitizer in radiofrequency hyperthermia for cancer treatment
title Transferrin as a thermosensitizer in radiofrequency hyperthermia for cancer treatment
title_full Transferrin as a thermosensitizer in radiofrequency hyperthermia for cancer treatment
title_fullStr Transferrin as a thermosensitizer in radiofrequency hyperthermia for cancer treatment
title_full_unstemmed Transferrin as a thermosensitizer in radiofrequency hyperthermia for cancer treatment
title_short Transferrin as a thermosensitizer in radiofrequency hyperthermia for cancer treatment
title_sort transferrin as a thermosensitizer in radiofrequency hyperthermia for cancer treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131143/
https://www.ncbi.nlm.nih.gov/pubmed/30202000
http://dx.doi.org/10.1038/s41598-018-31232-9
work_keys_str_mv AT chungheajong transferrinasathermosensitizerinradiofrequencyhyperthermiaforcancertreatment
AT leeheuikwan transferrinasathermosensitizerinradiofrequencyhyperthermiaforcancertreatment
AT kwonkibeom transferrinasathermosensitizerinradiofrequencyhyperthermiaforcancertreatment
AT kimhyeonjin transferrinasathermosensitizerinradiofrequencyhyperthermiaforcancertreatment
AT hongseongtshool transferrinasathermosensitizerinradiofrequencyhyperthermiaforcancertreatment